Lupin subsidiaries partner with Italian pharma firm to market gastro brand Plasil in Philippines and BrazilLupin subsidiaries partner with Italian pharma firm to market gastro brand Plasil in Philippines and Brazil

Introduction

Leading pharmaceutical company signed exclusive licensing agreements for Plasil® in the Philippines and Brazil, enhancing its gastroenterology portfolio and expanding presence in emerging markets with local production and supply arrangements.

Also Read: Paytm receives RBI Authorisation for physical and cross-border payments, One 97 Communications stocks in focus

Share price movement of Lupin

On December 19, 2025, Lupin Ltd opened at ₹2,127.00, up 0.42% from its previous close of ₹2,118.25. The stock reached a high of ₹2,146.80 (1.36%) and a low of ₹2,123.15. By 11:07 AM, it traded at ₹2,128.20, a 0.47% increase, with a market cap of ₹97,215.92 crore.

Lupin Secures Plasil® Licensing Philippines, Brazil

Lupin Limited announced an exclusive licensing agreement with Neopharmed Gentili S.p.A for its gastroenterology brand Plasil® in the Philippines and Brazil. The deal covers marketing and promotional rights in both markets.

Lupin’s subsidiaries, Multicare Pharmaceuticals in the Philippines and MedQuimica in Brazil, will manage the brand locally. Neopharmed will supply the product in the Philippines, while production shifts to MedQuimica’s facility in Brazil.

Plasil® treats nausea, vomiting, and motility disorders. The agreement strengthens Lupin’s gastroenterology portfolio and expands its presence in emerging markets, providing access to millions of patients in both countries.

Stock performance of Lupin for Period of 1 week, 6 months, and 1 year

Lupin Ltd delivered a 0.25% return over the past week. The stock gained 8.78% in the past six months and declined 2.02% over the past year.

Also Read: Cyient Ltd gains after subsidiary to acquire a majority stake in Kinetic Technologies

Shareholding pattern of Lupin

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	46.90%	46.90%	46.90%
FII	20.50%	21.30%	21.50%
DII	26.60%	25.60%	25%
Public	6.10%	6.30%	6.20%

About Lupin

Lupin Limited (NSE: LUPIN) is a global pharmaceutical leader headquartered in Mumbai, specializing in branded and generic formulations, biotechnology products, and APIs, with operations in over 100 markets and 15 manufacturing sites.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs